drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic drug)
drug_description
Recombinant humanized IgG1 monoclonal antibody targeting HER2 (ErbB2); administered IV (4 mg/kg loading then 2 mg/kg weekly, or 8 mg/kg loading then 6 mg/kg every 3 weeks). Binds the HER2 extracellular domain, inhibits receptor activation/dimerization and shedding, suppresses PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling, and induces ADCC via FcγR-bearing immune effector cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Trastuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting HER2 (ErbB2); binds the extracellular domain to block receptor activation and dimerization and inhibit shedding, thereby suppressing downstream PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling, while engaging FcγR-expressing immune cells to mediate ADCC against HER2-overexpressing tumor cells.
drug_name
Trastuzumab BS (trastuzumab biosimilar 3)
nct_id_drug_ref
NCT04181333